Singapore’s Bio*One Capital Eyes Services, Data and Devices In Investment Push: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
The biomedical investment arm of Singapore’s state-run investment firm EDBI, gives PharmAsia News insight into where its next round of investments are aimed.
You may also be interested in...
As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups
SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions
GSK And Singapore's Economic Development Board Finance Asian Public Health Research Through Public-Private Fund
SINGAPORE - The National University of Singapore has set up an initiative to advance public health and healthcare delivery in Asia. The 10-year initiative will be funded with S$17 million ($12.3 million) from the GSK-EDB Trust Fund, a joint fund created by GlaxoSmithKline and Singapore's Economic Development Board
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.